Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

273.12 -3.27 (-1.18%)
Streaming Delayed Price Updated: 1:41 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
56 57 Next >
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?
Via The Motley Fool
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
The U.S. stock market traded mixed on Tuesday morning, with major indices showing tight movements as investors awaited the release of the Federal Reserve's November meeting minutes. 
Via Benzinga
Topics Economy
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis. 
Via Benzinga
Pain In Retail
It’s been a relatively busy morning for earnings, especially from retailers. Of the ten companies reporting, six topped EPS forecasts, seven beat sales forecasts, but two, Best Buy and Kohl’s lowered... 
Via Talk Markets
Topics Stocks / Equities
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test
Over the course of a year, Amgen's MariTide helped patients lose about 20% of their body weight. 
Via Investor's Business Daily
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
Amgen's Phase 2 MariTide trial showed ~20% weight loss at 52 weeks, cardiometabolic improvements, and no significant safety issues. 
Via Benzinga
Investing in Pharma Stocks? Check These 3 Things First
Via The Motley Fool
Decoding Amgen's Options Activity: What's the Big Picture?
 
Via Benzinga
Amgen's Options Frenzy: What You Need to Know
 
Via Benzinga
What Analysts Are Saying About Amgen Stock
 
Via Benzinga
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
Via Investor's Business Daily
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity? 
Via Benzinga
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges. 
Via Benzinga
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone
 
Via Benzinga
Topics Stocks
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
Its future is bright, but that doesn't mean it'll always be smooth sailing. 
Via The Motley Fool
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends. 
Via The Motley Fool
2 Dividend Stocks to Buy Hand Over Fist in November
These companies have solid businesses and excellent dividend growth track records. 
Via The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
Shares were rattled Tuesday after a report showed its obesity treatment can cause lower bone mineral density. 
Via Investor's Business Daily
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could... 
Via Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
The company is testing MariTide as a monthly shot, rivaling weekly injections from Novo Nordisk and Eli Lilly. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Don’t Confuse Brains With A Bull Market, Or Price With Value
If you are interested in the stock market, maybe it is time to stop focusing on The Fed. 
Via Talk Markets
Investors Like Certainty. Trump's Win Gave Them Some.
We're also talking about Super Micro, Nvidia, and weight loss. 
Via The Motley Fool
Topics Government
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.